1. 肠道微生物对代谢性及免疫性疾病的影响及其具体分子机制

2. 微生物相关生物疗法，尤其是噬菌体疗法

学术成果

（#共同第一作者，*通讯作者）：

1.     Duan Y#, Llorente C#, Lang S, Brandl K, Chu H, Jiang L, et al., (2019). Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 575(7783): 505-511. doi: 10.1038/s41586-019-1742-x.

Recommended by Faculty of 1000 (Two recommendations from two independent experts). https:/f1000.com/prime/736896846

Featured article and highlighted in Nature, Science, Cell, Nature Reviews Drug Discovery, Nature Reviews Gastroenterology & Hepatology, Hepatology and Environmental Microbiology:

Microbial clues to a liver disease. Nature. doi: 10.1038/d41586-019-03417-3

Toxic gut bacteria make alcohol-triggered liver disease more deadly. Science. doi: 10.1126/science.aba2064

Bacteriophage prevents alcoholic liver disease. Cell. doi: 10.1016/j.cell.2019.12.034

Phages fight alcoholic hepatitis. Nature Reviews Drug Discovery. doi: 10.1038/d41573-019-00198-2

Manipulating the gut microbiota to combat alcoholic hepatitis. Nature Reviews Gastroenterology & Hepatology. doi: 10.1038/s41575-019-0246-3

Phage therapy for alcoholic hepatitis. Hepatology. doi: 10.1002/hep.31623

Hope for alcoholics from phage therapy? Environmental Microbiology. doi: 10.1111/1462-2920.14898

2.     Shi Y#, Chen Z#, Fang T#, Chen X, Deng Y, et al., Duan Y*. (2024). Gut microbiota in treating inflammatory digestive diseases: current challenges and therapeutic opportunities. iMeta. e265. doi: 10.1002/imt2.265.

3.     Deng Y#, Jiang S#*, Duan H, Shao H, Duan Y*. (2024). Bacteriophages and their potential for treatment of metabolic diseases. Journal of Diabetes. 16(11):e70024. doi: 10.1111/1753-0407.70024.

4.     Xie S#, Li J#, Lyu F#, Xiong Q#, et al., Duan Y*, Jiang Y*, Zhou H*, Chen P*. (2023). Novel tripeptide RKH derived from Akkermansia muciniphila protects against lethal sepsis. Gut. 14(3):490. doi: 10.1136/gutjnl-2023-329996.

5.     Chen X#, Mendes BG#*, Alves BS, Duan Y*. (2023). Phage therapy in gut microbiome. Progress in Molecular Biology and Translational Science. doi: 10.1016/bs.pmbts.2023.04.005.

6.     Mendes BG#, Duan Y#, Schnabl B. (2022). Immune response of an oral Enterococcus faecalis phage cocktail in a mouse model of ethanol-induced liver disease. Viruses. 14(3):490. doi: 10.3390/v14030490.

7.     Duan Y, Young R, Schnabl B (2022). Bacteriophages and their potential for treatment of gastrointestinal diseases. Nature Reviews Gastroenterology & Hepatology. 19(2):135-144. doi: 10.1038/s41575-021-00536-z.

8.     Duan Y#, Chu H#, Brandl K, Jiang L, Zeng S, Mendes BG, et al., (2021). CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nature Communications. 12(1):7172. doi: 10.1038/s41467-021-27385-3.

9.     Chu H#, Duan Y#, Lang S, Jiang L, Wang Y, Llorente C, et al., (2020). The Candida albicans exotoxin Candidalysin promotes alcohol-associated liver disease. Journal of Hepatology. 72(3):391-400. doi: 10.1016/j.jhep.2019.09.029. (2019 AASLD Early Career Investigator Award)

10.  Gao B#, Duan Y#, Lang S, Barupal D, Wu TC, Valdiviez L, et al., (2020). Functional microbiomics reveals alterations of the gut microbiome and host co-metabolism in patients with alcoholic hepatitis. Hepatology Communications. 4(8):1168-1182. doi: 10.1002/hep4.1537. (Journal Cover)

11.  Duan Y, Huey JD, Herman JK (2016). The DnaA inhibitor SirA acts in the same pathway as Soj (ParA) to facilitate oriC segregation during Bacillus subtilis sporulation. Molecular Microbiology. 102(3):530-544. doi: 10.1111/mmi.13477.

12.  Duan Y#, Sperber AM#, Herman JK (2016). YodL and YisK possess shape-modifying activities that are suppressed by mutations in Bacillus subtilis mreB and mbl. Journal of Bacteriology. 198(15):2074-2088. doi: 10.1128/JB.00183-16.

13.  Kuang X, Shen J, Zheng L, Duan Y, Ma Y, Leung E, Dai L. (2025). Applications of bacteriophages in precision engineering of the human gut microbiome. Engineering Microbiology.100189. doi: 10.1016/j.engmic.2025.100189.

14.  Au K#, Zheng MH#, Lee WJ, et al., Global Obesity Collaborative. Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals. (2024). Current Obesity Reports.13(4):818-830. doi:10.1007/s13679-024-00582-z. （以Global Obesity Collaborative成员身份参与发表）

15.  Wang Yao, Hou H, Hao L, et al., Duan Y et al., iMeta Conference 2024: Building an innovative scientific research ecosystem for microbiome and One Health. iMeta. e251. doi: 10.1002/imt2.251.

16.  Zeng S, Rosati E, Saggau C, Messner B, Chu H, Duan Y, Hartmann P, et al., (2023). Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe. 31(3):389-404. doi: 10.1016/j.chom.2023.02.001.

17.  Demir M#, Lang S#, Hartmann P#, Duan Y, Martin A, Miyamoto Y, Bondareva M, et al., (2022). The fecal mycobiome in non-alcoholic fatty liver disease. Journal of Hepatology. 76(4):788-799. doi: 10.1016/j.jhep.2021.11.029.

18.  Hsu CL, Duan Y, Fouts DE, Schnabl B. (2021). Intestinal virome and therapeutic potential of bacteriophages in liver disease. Journal of Hepatology. 75(6):1465-1475. doi: 10.1016/j.jhep.2021.08.003.

19.  Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs L, et al., (2021). Gut microbiome directs hepatocytes to recruit MDSC and promote cholangiocarcinoma. Cancer Discovery. 11(5):1248-1267. doi: 10.1158/2159-8290.CD-20-0304.

20.  Jiang L#, Lang S#, Duan Y, Zhang X, Gao B, Chopyk J, et al., (2020). Intestinal virome in patients with alcoholic hepatitis. Hepatology. 72(6):2182-2196. doi: 10.1002/hep.31459.

21.  Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, et al., (2020). Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology. 71(2):522-538. doi: 10.1002/hep.30832.

22.  Lang S#, Demir M#, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, et al., (2020). Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology. 159(5):1839-1852. doi: 10.1053/j.gastro.2020.07.005.

23.  Hendrikx T, Duan Y, Wang Y, Oh JH, Alexander LM, Huang W, et al., (2019). Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut. 68(8):1504-1515. doi: 10.1136/gutjnl-2018-317232.

24.  Chu H, Duan Y, Yang L, and Schnabl B (2019). Small Metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 68(2):359-370. doi: 10.1136/gutjnl-2018-316307.

25.  Zeng S, Hartmann P, Park M, Duan Y, Lang S, Llorente C, Wang Y, et al., (2023). Malassezia restricta promotes alcohol-induced liver injury. Hepatology Communications. 7(2):e0029. doi: 10.1007/s12072-022-10296-w.

26.  Guo T, Sperber AM, Krieger IV, Duan Y, Chemelewski VR, Sacchettini JC, et al., (2023). Bacillus subtilis YisK possesses oxaloacetate decarboxylase activity and exhibits Mbl-dependent localization. Journal of Bacteriology. doi: 10.1128/jb.00202-23.

27.  Kouno T, Zeng S, Wang Y, Duan Y, Lang S, Gao B, Hartmann P, et al., (2023). Engineered bacteria producing aryl-hydrocarbon receptor agonists protect against ethanol-induced liver disease in mice. Alcohol: Clinical and Experimental Research. 47(5):856-867. doi: 10.1111/acer.15048.

28.  Hsu CL, Wang Y, Duan Y, Chu H, Hartmann P, Llorente C, Zhou R, et al., (2023). Differences in bacterial translocation and liver injury in ethanol versus diet-induced liver disease. Digestive Diseases and Sciences. 68(7):3059-3069. doi: 10.1007/s10620-023-07860-1.

29.  Hartmann P, Duan Y, Miyamoto Y, Demir M, Lang S, Hasa E, Stern P, et al., (2022). Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice. Hepatology International. 16(2):359-370. doi: 10.1097/HC9.0000000000000029.

30.  Gao B#, Wu T-C#, Lang S, Jiang L, Duan Y, Fouts DE, Zhang X, et al., (2022). Machine learning applied to omics datasets predicts mortality in patients with alcoholic hepatitis. Metabolites. 12(1):41. doi: 10.3390/metabo12010041.

31.  Hartmann P, Lang S, Zeng S, Duan Y, Zhang X, Wang Y, Bondareva M, et al., (2021). Dynamic changes of the fungal microbiome in alcohol use disorder. Frontiers in Physiology. 12:699253. doi: 10.3389/fphys.2021.699253.

32.  Cabre N, Duan Y, Llorente C, Conrad M, Stern P, Yamashita D, Schnabl B. (2021) Colesevelam reduces ethanol-induced liver steatosis in humanized gnotobiotic mice. Cells. 10(6):1496. doi: 10.3390/cells10061496.

33.  Chu H, Jiang L, Gao B, Gautam N, Alamoudi J, Lang S, Wang Y, Duan Y, Alnouti Y, et al., (2021). The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. Translational Research. 227:1-14. doi: 10.1016/j.trsl.2020.06.006.

34.  Lang S#, Fairfied B#, Gao B#, Duan Y, Zhang X, Fouts DE, et al., (2020) Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients. Gut Microbes. 12(1):1785251. doi: 10.1080/19490976.2020.1785251.

35.  Lang S#, Demir M#, Duan Y, Martin A, Schnabl B. (2020). Cytolysin-positive Enterococcus faecalis is not increased in patients with non-alcoholic steatohepatitis. Liver International. 40(4):860-865. doi: 10.1111/liv.14377.

36.  Jiang L, Chu H, Gao B, Lang S, Wang Y, Duan Y, Schnabl B. (2020). Transcriptomic profiling identifies novel hepatic and intestinal genes following chronic plus binge ethanol feeding in mice. Digestive Diseases and Sciences. 65(12):3592-3604. doi: 10.1007/s10620-020-06461-6.

37.  Zhou R#, Llorente C#, Cao J, Gao B, Duan Y, Jiang L, Wang Y, Kumar V, et al., (2020). Deficiency of a1-2-fucosylation exacerbates ethanol-induced liver disease in mice. Alcohol: Clinical and Experimental Research. 44(9):1842-1851. doi: 10.1111/acer.14405.

38.  Gao B, Emami A, Zhou R, Lang S, Duan Y, Wang Y, Jiang L, et al., (2020). Functional microbial responses to alcohol abstinence in patients with alcohol use disorder. Frontiers in Physiology. 11:370. doi: 10.3389/fphys.2020.00370.

39.  Hartmann P#, Chu H#, Duan Y, Schnabl B (2019). Gut microbiota in liver disease: Too much is harmful, nothing at all is not helpful either. American Journal of Physiology – Gastrointestinal and Liver Physiology. 316(5):G563-G573. doi: 10.1152/ajpgi.00370.2018.

40.  Gao B, Lang S, Duan Y, Wang Y, Shawcross DL, et al., (2019). Serum and fecal oxylipins in patients with alcohol-related liver disease. Digestive Diseases and Sciences. 64(7):1878-1892. doi: 10.1007/s10620-019-05638-y.